Neuropathic Pain Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for neuropathic pain. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neuropathic pain market from 2025 to 2032.

Key Insights:

Neuropathic Pain Market Size (2025E): USD9.1 Billion
Projected Market Value (2032F): USD 13.2 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Neuropathic Pain Market - Report Scope:

Neuropathic pain refers to chronic pain resulting from damage to the somatosensory nervous system and is commonly associated with conditions such as diabetes, cancer, spinal cord injuries, postherpetic neuralgia, and multiple sclerosis. The market encompasses a range of pharmacological treatments-including anticonvulsants, antidepressants, opioids, topical agents, and others-administered through various routes. The market serves hospitals, clinics, retail pharmacies, and outpatient settings worldwide, with demand driven by improved diagnostics, aging populations, and increasing prevalence of chronic diseases that cause nerve damage.

Market Growth Drivers:

The global neuropathic pain market is driven by the rising global prevalence of diabetes, cancer, and other chronic conditions that elevate nerve damage risk. Diabetic neuropathy, in particular, represents a major indication given the high incidence of diabetes worldwide. Improvements in diagnostic capabilities and expanded access to pain management therapies contribute to greater treatment uptake. Furthermore, a shift toward non-opioid alternatives due to concerns around opioid addiction and regulatory pressures supports demand for safer, more effective therapeutic options.

Market Restraints:

Despite positive growth prospects, the neuropathic pain market faces challenges due to severe side effects associated with some pain management medications and the high cost of branded therapies, particularly in developing regions. These financial and safety concerns can hinder market adoption and limit access to advanced treatments in cost-sensitive markets.

Market Opportunities:

There is a significant unmet need for disease-modifying treatments that target underlying pathophysiological mechanisms of nerve damage rather than solely alleviating pain symptoms. Advances in neurobiology, gene therapy, and biomarker-driven strategies present opportunities to develop novel therapies aimed at nerve regeneration and long-term outcomes. Personalized pain management approaches and combination therapies also offer growth potential.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the neuropathic pain market globally?
Which drug classes and indications are dominating market demand?
How are treatment innovations and non-opioid approaches shaping the competitive landscape?
Who are the key players in the neuropathic pain market, and what strategies are they employing?
What are the emerging trends and future prospects in the global neuropathic pain market?

Competitive Intelligence and Business Strategy:

Leading players in the global neuropathic pain market focus on expanding product portfolios, advancing clinical research, and forming strategic collaborations to enhance competitiveness. Firms emphasize development of targeted therapies with better efficacy and safety profiles, while partnerships with healthcare providers and research institutions support innovations and market penetration. Emphasis on patient-centric care, personalized medicine, and combination treatment strategies is key to capturing market share in a competitive landscape.

Key Companies Profiled:

Almatica
Vertex Pharmaceuticals Incorporated
Azurity Pharmaceuticals, Inc.
Pfizer Inc.
Viatris Inc.
Supernus Pharmaceuticals, Inc.
Novartis AG
Accord Healthcare
Focus Health Group
Amneal Pharmaceuticals LLC
Abbott
Teva Pharmaceutical Industries Ltd.

Neuropathic Pain Market Research Segmentation:

By Drug Class:

Anticonvulsants
Tricyclic Antidepressants
SNRI's
Topical Anesthetics
Opioids

By Indication:

Diabetic Neuropathy
Post-herpetic Neuralgia
Spinal Cord Injury

By Route of Administration:

Oral
Parenteral
Topical

By Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region:

North America
Europe
East Asia
South Asia and Oceania
Middle East and Africa
Latin America

Product Code: PMRREP4149

1. Executive Summary

1.1. Global Neuropathic Pain Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. COVID-19 Impact Analysis
2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Disease Epidemiology
3.2. Value Chain Analysis
3.3. Technology Assessment
3.4. Product Adoption / Usage Analysis
3.5. Recent Product Approvals & Launches
3.6. Key Market Players
3.7. Regulatory Landscape
3.8. PESTLE Analysis
3.9. Porter's Five Force Analysis

4. Global Neuropathic Pain Market Outlook

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
4.3. Global Neuropathic Pain Market Outlook: Drug Class
- 4.3.1. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
- 4.3.2. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
  - 4.3.2.1. Tricyclic Anti-Depressants
  - 4.3.2.2. Anticonvulsants
  - 4.3.2.3. SNRI's
  - 4.3.2.4. Topical Anesthetics
  - 4.3.2.5. Opioids
  - 4.3.2.6. Others
- 4.3.3. Market Attractiveness Analysis: Drug Class
4.4. Global Neuropathic Pain Market Outlook: Indication
- 4.4.1. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
- 4.4.2. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
  - 4.4.2.1. Diabetic Neuropathy
  - 4.4.2.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  - 4.4.2.3. Post-Herpetic Neuralgia (PHN)
  - 4.4.2.4. Trigeminal Neuralgia
  - 4.4.2.5. Spinal Cord Injury-Associated Neuropathy
  - 4.4.2.6. Phantom Limb Pain
  - 4.4.2.7. Multiple Sclerosis-Associated Neuropathy
  - 4.4.2.8. Others
- 4.4.3. Market Attractiveness Analysis: Indication
4.5. Global Neuropathic Pain Market Outlook: Route of Administration
- 4.5.1. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
- 4.5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
  - 4.5.2.1. Oral
  - 4.5.2.2. Topical
  - 4.5.2.3. Parenteral
- 4.5.3. Market Attractiveness Analysis: Route of Administration
4.6. Global Neuropathic Pain Market Outlook: Distribution Channel
- 4.6.1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
- 4.6.2. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
  - 4.6.2.1. Hospital Pharmacies
  - 4.6.2.2. Retail Pharmacies
  - 4.6.2.3. Online Pharmacies
- 4.6.3. Market Attractiveness Analysis: Distribution Channel

5. Global Neuropathic Pain Market Outlook: Region

5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Region, 2024-2032
- 5.2.1. North America
- 5.2.2. Latin America
- 5.2.3. Europe
- 5.2.4. East Asia
- 5.2.5. South Asia and Oceania
- 5.2.6. Middle East & Africa
5.3. Market Attractiveness Analysis: Region

6. North America Neuropathic Pain Market Outlook

6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 6.1.1. By Country
- 6.1.2. By Drug Class
- 6.1.3. By Indication
- 6.1.4. By Route of Administration
- 6.1.5. By Distribution Channel
6.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 6.2.1. U.S.
- 6.2.2. Canada
6.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 6.3.1. Tricyclic Anti-Depressants
- 6.3.2. Anticonvulsants
- 6.3.3. SNRI's
- 6.3.4. Topical Anesthetics
- 6.3.5. Opioids
- 6.3.6. Others
6.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 6.4.1. Diabetic Neuropathy
- 6.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 6.4.3. Post-Herpetic Neuralgia (PHN)
- 6.4.4. Trigeminal Neuralgia
- 6.4.5. Spinal Cord Injury-Associated Neuropathy
- 6.4.6. Phantom Limb Pain
- 6.4.7. Multiple Sclerosis-Associated Neuropathy
- 6.4.8. Others
6.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 6.5.1. Oral
- 6.5.2. Topical
- 6.5.3. Parenteral
6.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies
- 6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis

7. Europe Neuropathic Pain Market Outlook

7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.1.1. By Country
- 7.1.2. By Drug Class
- 7.1.3. By Indication
- 7.1.4. By Route of Administration
- 7.1.5. By Distribution Channel
7.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. U.K.
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 7.3.1. Tricyclic Anti-Depressants
- 7.3.2. Anticonvulsants
- 7.3.3. SNRI's
- 7.3.4. Topical Anesthetics
- 7.3.5. Opioids
- 7.3.6. Others
7.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 7.4.1. Diabetic Neuropathy
- 7.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 7.4.3. Post-Herpetic Neuralgia (PHN)
- 7.4.4. Trigeminal Neuralgia
- 7.4.5. Spinal Cord Injury-Associated Neuropathy
- 7.4.6. Phantom Limb Pain
- 7.4.7. Multiple Sclerosis-Associated Neuropathy
- 7.4.8. Others
7.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 7.5.1. Oral
- 7.5.2. Topical
- 7.5.3. Parenteral
7.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies
- 7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis

8. East Asia Neuropathic Pain Market Outlook

8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.1.1. By Country
- 8.1.2. By Drug Class
- 8.1.3. By Indication
- 8.1.4. By Route of Administration
- 8.1.5. By Distribution Channel
8.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 8.2.1. China
- 8.2.2. Japan
- 8.2.3. South Korea
8.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 8.3.1. Tricyclic Anti-Depressants
- 8.3.2. Anticonvulsants
- 8.3.3. SNRI's
- 8.3.4. Topical Anesthetics
- 8.3.5. Opioids
- 8.3.6. Others
8.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 8.4.1. Diabetic Neuropathy
- 8.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 8.4.3. Post-Herpetic Neuralgia (PHN)
- 8.4.4. Trigeminal Neuralgia
- 8.4.5. Spinal Cord Injury-Associated Neuropathy
- 8.4.6. Phantom Limb Pain
- 8.4.7. Multiple Sclerosis-Associated Neuropathy
- 8.4.8. Others
8.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 8.5.1. Oral
- 8.5.2. Topical
- 8.5.3. Parenteral
8.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies
- 8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis

9. South Asia & Oceania Neuropathic Pain Market Outlook

9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.1.1. By Country
- 9.1.2. By Drug Class
- 9.1.3. By Indication
- 9.1.4. By Route of Administration
- 9.1.5. By Distribution Channel
9.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 9.2.1. India
- 9.2.2. Indonesia
- 9.2.3. Thailand
- 9.2.4. Singapore
- 9.2.5. ANZ
- 9.2.6. Rest of South Asia & Oceania
9.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 9.3.1. Tricyclic Anti-Depressants
- 9.3.2. Anticonvulsants
- 9.3.3. SNRI's
- 9.3.4. Topical Anesthetics
- 9.3.5. Opioids
- 9.3.6. Others
9.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 9.4.1. Diabetic Neuropathy
- 9.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 9.4.3. Post-Herpetic Neuralgia (PHN)
- 9.4.4. Trigeminal Neuralgia
- 9.4.5. Spinal Cord Injury-Associated Neuropathy
- 9.4.6. Phantom Limb Pain
- 9.4.7. Multiple Sclerosis-Associated Neuropathy
- 9.4.8. Others
9.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 9.5.1. Oral
- 9.5.2. Topical
- 9.5.3. Parenteral
9.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies
- 9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis

10. Latin America Neuropathic Pain Market Outlook

10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.1.1. By Country
- 10.1.2. By Drug Class
- 10.1.3. By Indication
- 10.1.4. By Route of Administration
- 10.1.5. By Distribution Channel
10.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 10.2.1. Brazil
- 10.2.2. Mexico
- 10.2.3. Rest of Latin America
10.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 10.3.1. Tricyclic Anti-Depressants
- 10.3.2. Anticonvulsants
- 10.3.3. SNRI's
- 10.3.4. Topical Anesthetics
- 10.3.5. Opioids
- 10.3.6. Others
10.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 10.4.1. Diabetic Neuropathy
- 10.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 10.4.3. Post-Herpetic Neuralgia (PHN)
- 10.4.4. Trigeminal Neuralgia
- 10.4.5. Spinal Cord Injury-Associated Neuropathy
- 10.4.6. Phantom Limb Pain
- 10.4.7. Multiple Sclerosis-Associated Neuropathy
- 10.4.8. Others
10.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 10.5.1. Oral
- 10.5.2. Topical
- 10.5.3. Parenteral
10.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis

11. Middle East & Africa Neuropathic Pain Market Outlook

11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 11.1.1. By Country
- 11.1.2. By Drug Class
- 11.1.3. By Indication
- 11.1.4. By Route of Administration
- 11.1.5. By Distribution Channel
11.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 11.2.1. GCC Countries
- 11.2.2. Egypt
- 11.2.3. South Africa
- 11.2.4. Northern Africa
- 11.2.5. Rest of Middle East & Africa
11.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 11.3.1. Tricyclic Anti-Depressants
- 11.3.2. Anticonvulsants
- 11.3.3. SNRI's
- 11.3.4. Topical Anesthetics
- 11.3.5. Opioids
- 11.3.6. Others
11.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 11.4.1. Diabetic Neuropathy
- 11.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 11.4.3. Post-Herpetic Neuralgia (PHN)
- 11.4.4. Trigeminal Neuralgia
- 11.4.5. Spinal Cord Injury-Associated Neuropathy
- 11.4.6. Phantom Limb Pain
- 11.4.7. Multiple Sclerosis-Associated Neuropathy
- 11.4.8. Others
11.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 11.5.1. Oral
- 11.5.2. Topical
- 11.5.3. Parenteral
11.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 11.6.1. Hospital Pharmacies
- 11.6.2. Retail Pharmacies
- 11.6.3. Online Pharmacies
11.7. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2024
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Almatica
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Sources
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Vertex Pharmaceuticals Incorporated
- 12.3.3. Azurity Pharmaceuticals, Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Viatris Inc.
- 12.3.6. Supernus Pharmaceuticals, Inc.
- 12.3.7. Novartis AG
- 12.3.8. Accord Healthcare
- 12.3.9. Focus Health Group
- 12.3.10. ABneal Pharmaceuticals LLC.
- 12.3.11. Abbott
- 12.3.12. Teva Pharmaceutical Industries Ltd.
- 12.3.13. Others

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations